Pacira BioSciences, Inc. Common Stock (PCRX) is a publicly traded Healthcare sector company. As of May 20, 2026, PCRX trades at $22.23 with a market cap of $882.97M and a P/E ratio of 140.38. PCRX moved -1.70% today. Year to date, PCRX is -8.79%; over the trailing twelve months it is -14.68%. Its 52-week range spans $13.89 to $27.64. Analyst consensus is buy with an average price target of $28.40. Rallies surfaces PCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own PCRX include Pinebridge Investments. The latest tracked quarter is Jun 30, 2023. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Pacira BioSciences, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $22.23 |
| Market Cap | $882.97M |
| P/E Ratio | 140.38 |
| EPS | $0.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.64 |
| 52-Week Low | $13.89 |
| Volume | 64.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $726.41M |
| Net Income | $7.03M |
| Gross Margin | 79.39% |
6 analysts cover PCRX: 0 strong buy, 3 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $28.40.